Company researchers showed that the agents could selectively target single point mutations not associated with protein-binding pockets.
Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
The MRM-MS-based method combines use of conventional stable isotope-labeled peptide standards with a series of endogenous protein standards.
The company hopes to launch the test sometime this year after completing CLIA certification of its clinical laboratory and securing reimbursement.
The agreement gives Caprion, which did significant development work on the test, exclusive rights to market and commercialize Xpresys Lung inCanada.
The 141-sample study found the test could identify benign lesions in lung cancer patients with a negative predictive value of between 84 percent and 98 percent.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
The collaboration will explore use of the PCC agents, which are synthetic peptides with functions similar to traditional antibodies, for protein research.
NEW YORK (GenomeWeb) – With a series of recent payor decisions, Integrated Diagnostics now has more than 200 million covered lives for its Xpresys Lung cancer test.
NEW YORK (GenomeWeb) – Integrated Diagnostics said today that recent payor decisions have given it more than 200 million covered lives for its Xpresys Lung cancer test.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.